title: In vitro evaluation of the antimicrobial efficacy of a new silver-triclosan vs a silver collagen-coated polyester vascular graft against methicillin-resistant Staphylococcus aureus.
abstract: OBJECTIVE
  Vascular graft infection is a rare but serious complication of vascular reconstructive surgery. This in vitro study investigated the antimicrobial efficacy of a new, silver-triclosan collagen-coated polyester vascular graft compared with a silver collagen-coated polyester vascular graft alone during the first 24 hours.
  
  
  METHODS
  The antimicrobial efficacy of the investigated vascular grafts was assessed by performing a time-kill kinetic assay following Clinical and Laboratory Institute Standards-approved guidelines M26-A. For the purpose of the experimental study, the ATCC 33591 strain of methicillin-resistant Staphylococcus aureus (American Type Culture Collection, Manassas, Va) was used. All assays were repeated sixfold. Bacterial survival numbers were obtained at 1, 4, 8, 12, and 24 hours using a standard plate count procedure. Bactericidal activity was defined as a 3 log(10) reduction factor (logRF), according to the approved guideline M26-A.
  
  
  RESULTS
  Both antimicrobial vascular grafts achieved >3 logRF and fulfilled the efficacy criterion for bactericidal activity but performed differently in their speed of antimicrobial action. The silver-triclosan vascular graft achieved 3.37 logRF after 8 hours, and the silver vascular graft showed a 4.19 logRF after 24 hours. The silver-triclosan graft yielded significantly lower colony-forming units/mL counts after 4 hours compared with the silver graft (4.29 × 10(4) vs 1.03 × 10(6); P = .031).
  
  
  CONCLUSIONS
  Both antimicrobial collagen-coated polymer vascular grafts showed bactericidal activity against methicillin-resistant Staphylococcus aureus in vitro. Although the silver-triclosan vascular graft showed a faster antimicrobial efficacy, the silver graft exhibited its antimicrobial properties after 24 hours. Which concept will protect an implanted vascular prosthetic graft better from bacterial contamination and subsequent infection needs to be investigated further in in vivo animal and clinical studies.
authors.affiliation: Vascular Surgery Department, University Hospital, Poitiers, France.
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Ricco
authors.forename: Afshin
authors.initials: A
authors.lastname: Assadian
authors.forename: Fabrice
authors.initials: F
authors.lastname: Schneider
authors.forename: Ojan
authors.initials: O
authors.lastname: Assadian
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D000891:Anti-Infective Agents, Local / Q000494:pharmacology*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D020099:Coated Materials, Biocompatible; D003094:Collagen; D015169:Colony Count, Microbial; D004337:Drug Carriers; D004338:Drug Combinations; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D050296:Microbial Viability / Q000187:drug effects; D011091:Polyesters; D011474:Prosthesis Design; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology; D018030:Silver Compounds / Q000494:pharmacology*; D013997:Time Factors; D014260:Triclosan / Q000494:pharmacology*
chemical_list: D000085:Acetates; D000891:Anti-Infective Agents, Local; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D004338:Drug Combinations; D011091:Polyesters; D018030:Silver Compounds; C103100:silver acetate; D014260:Triclosan; D003094:Collagen